0
Upcoming Allied Market Research
2023
Neurotrophic Keratitis Market

Neurotrophic Keratitis Market: Global Opportunity Analysis and Industry Forecast, 2023-2030 Market

Report Code: A10463
Nov 2023 | Pages: NA
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Neurotrophic Keratitis Market

Request Now !

Neurotrophic Keratitis is a neurodegenerative disorder which affects the cornea of an eye. Due to the affect on cornea, patient loses their corneal sensitivity as a result the cornea is exposed to eye injuries without curing. Injury to the trigeminal nerve can cause Neurotrophic Keratitis which lead to permanent vision loss if not diagnosed and treated properly. Diagnosis and treatment are done by a team comprising of ophthalmologists, neurologists, and corneal specialists. Various treatment are available in the neurotrophic keratitis market such as topical antibiotics, keratoplasty, bandage contact lenses, preservative artificial tears, amniotic membrane transplantation, Recombinant human nerve growth factor (rhNGF), treatments are available depending on the severity of the disease. The major parameters that are used to measure the efficacy of treatment such as corneal healing, corneal sensitivity, and duration of corneal healing, among others. The incidence of neurotrophic keratitis is low due to which, there were no approved drugs in the market to treat the rare eye disease. Researcher increasing their investments for the development and discovery of drugs that could potentially treat the rare eye disease. Progress in biotechnology has enabled the development of new biological treatments for neurotrophic keratitis. In 2018, the U.S. Food and Drug Administration has approved Oxervate, a drug developed by “Dompé”. “Oxervate”, was the first-ever drug to receive the approval from the FDA for the treatment of neurotrophic keratitis. 

Neurotrophic-Keratitis

COVID-19 Scenario Analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future. 

The ongoing outbreak of COVID-19 pandemic impacted the pharmaceutical industry positively. It affect neurotrophic keratitis market. The demand and supply chain for the neurotrophic keratitis drug product and their associated treatment reduce which affect the business of keratitis market player. Due to the temporarily shutting down of industries in various regions affect the research and development activities which hinder the neurotrophic keratitis market growth. 

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:

Globally, North America hold the largest market share of the neurotrophic keratitis and dominate overall market attributed to growing healthcare industry, presence of well-developed hospital facilities, growing product approvals, rising advance technology, increasing number of well-equipped laboratories, growing research & developmental activities in neurotrophic keratitis, and presence of major market players. However, Asia Pacific is expected to increase market growth rate due to rising geriatric population, increasing interest of market players in neurotropic keratitis, increasing research & developmental activities, and growing in initiatives by governments in the healthcare sector.

As per the report of “New York Eye and Ear Infirmary”, around 500,000 cases of keratitis found per year in developing countries and approximately 25,000 to 30,000 number of cases in the U.S. found every year. Keratitis is a leading causes of preventable blindness across the globe. “National Institute for Health Research” stated that, neurotrophic keratitis develops 149 per 100,000 population of herpetic keratitis patients and herpes zoster keratitis patients 26 per 100,000 population. Additionally, 1.5 per 10,000 population patients who underwent surgical procedures for trigeminal neuralgia consequently developed neurotrophic keratitis.

The factors that drive the growth of neurotrophic keratitis market such as increasing geriatric population, increasing investments in research and development activities, growing demand for advanced neurotrophic keratitis therapy, rising number of product approvals and launches, rising interest of market player and their strategies to develop the market growth, and increasing incidence of keratitis which rises the number of cases of neurotrophic keratitis. The factor that restrain the growth of neurotrophic keratitis market such ad high cost of chronic use of topical eye gels and drops such as RGTA technology based solutions. The challenges faced by neurotrophic keratitis market player including increasing demand for autologous serum drops production and low cost of treatment of neurotrophic keratitis 

New Product launch to flourish the market:

Major Key market manufacturer have been focusing on increasing research and development activities and producing new product solution for specific applications as there are varying demands based on the utilization. Leading market players have determined how improved accuracy can be influential in many applications. Market player adopted various strategies to operate global neurotrophic market. 

In 2019, “Dompé” has introduce new therapy in neurotrophic market such as “Oxervate”, this therapy commonly used for the treatment of  neurotrophic keratitis (NK), which is a rare and progressive eye disease that can lead to corneal scarring and vision loss.

In 2019, “RegeneRx Biopharmaceuticals, Inc.” has received U.S.FDA approval for Tβ4 with non-active ingredients patent which provide improved pharmacodynamics. This patent product used for a method of preventing or treating dry eye syndrome. 

In 2018, “Allergen” has launched new therapy such as “Acular (ketorolac tromethamine) Ophthalmic Solution” is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve eye itching caused by seasonal allergies. Acular is also used to reduce swelling, pain, and burning or stinging after cataract surgery or corneal refractive surgery. It is available in generic form.

In 2017, “Santen Pharmaceutical Co., Ltd” enter into collaboration with “Singapore Eye Research Institute” for developing new technologies for unmet medical needs in key ophthalmology domain

In 2016, “Allergan plc” has launched “ForSight VISION5,” a privately held, clinical-stage biotechnology company focused on eye care.

Key benefits of the report:

  • This study presents the analytical depiction of the global neurotrophic keratitis market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global neurotrophic keratitis market share.
  • The current market is quantitatively analyzed to highlight the global neurotrophic keratitis market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global neurotrophic keratitis market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Neurotrophic Keratitis Market research report:

  • Who are the leading market players active in neurotrophic keratitis market?
  • What are the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

Neurotrophic Keratitis Market: Global Opportunity Analysis and Industry Forecast, 2020–2027 Report Highlights

Aspects Details
By Treatment Type
  • Artificial Tear
  • Recombinant Human Nerve Growth Factor Eye Drop
  • Antibiotic
  • Bandage Contact Lenses
  • Others
By Surgical Intervention
  • Tarsorrhaphy
  • Aminoitic Membrane Transplantation
  • Others
By Application
  • Stage II
  • Stage II
  • Stage III
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
By End User
  • Biotechnology Company
  • Hospital
  • Clinic
Key Market Players Bausch & Lomb Incorporated,, OHTO Pharmaceutical Co., Ltd.,, Zhejiang CONBA Pharmaceutical Co., Ltd., Neuroptika,, Johnson & Johnson,, Allergan, ReGenTree, LLC,, CONTACARE,, Santen Pharmaceutical Co., Ltd.,, Grand Pharma, Co., Ltd.,, Alcon,, Dompe farmaceutici S.p.A.,, Pfizer, Inc.,
 
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: NEUROTROPHIC KERATITIS MARKET, BY TREATMENT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Treatment Type

    • 4.2. Artificial Tear

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Recombinant Human Nerve Growth Factor Eye Drop

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Antibiotic

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Bandage Contact Lenses

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Others

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: NEUROTROPHIC KERATITIS MARKET, BY SURGICAL INTERVENTION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Surgical Intervention

    • 5.2. Tarsorrhaphy

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Aminoitic Membrane Transplantation

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Others

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: NEUROTROPHIC KERATITIS MARKET, BY APPLICATION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Application

    • 6.2. Stage II

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Stage II

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Stage III

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: NEUROTROPHIC KERATITIS MARKET, BY END USER

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By End User

    • 7.2. Biotechnology Company

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Hospital

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Clinic

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

  • CHAPTER 8: NEUROTROPHIC KERATITIS MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Treatment Type

      • 8.2.3. Market Size and Forecast, By Surgical Intervention

      • 8.2.4. Market Size and Forecast, By Application

      • 8.2.5. Market Size and Forecast, By End User

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Neurotrophic Keratitis Market

        • 8.2.7.1. Market Size and Forecast, By Treatment Type
        • 8.2.7.2. Market Size and Forecast, By Surgical Intervention
        • 8.2.7.3. Market Size and Forecast, By Application
        • 8.2.7.4. Market Size and Forecast, By End User
      • 8.2.8. Canada Neurotrophic Keratitis Market

        • 8.2.8.1. Market Size and Forecast, By Treatment Type
        • 8.2.8.2. Market Size and Forecast, By Surgical Intervention
        • 8.2.8.3. Market Size and Forecast, By Application
        • 8.2.8.4. Market Size and Forecast, By End User
      • 8.2.9. Mexico Neurotrophic Keratitis Market

        • 8.2.9.1. Market Size and Forecast, By Treatment Type
        • 8.2.9.2. Market Size and Forecast, By Surgical Intervention
        • 8.2.9.3. Market Size and Forecast, By Application
        • 8.2.9.4. Market Size and Forecast, By End User
    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Treatment Type

      • 8.3.3. Market Size and Forecast, By Surgical Intervention

      • 8.3.4. Market Size and Forecast, By Application

      • 8.3.5. Market Size and Forecast, By End User

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Neurotrophic Keratitis Market

        • 8.3.7.1. Market Size and Forecast, By Treatment Type
        • 8.3.7.2. Market Size and Forecast, By Surgical Intervention
        • 8.3.7.3. Market Size and Forecast, By Application
        • 8.3.7.4. Market Size and Forecast, By End User
      • 8.3.8. Germany Neurotrophic Keratitis Market

        • 8.3.8.1. Market Size and Forecast, By Treatment Type
        • 8.3.8.2. Market Size and Forecast, By Surgical Intervention
        • 8.3.8.3. Market Size and Forecast, By Application
        • 8.3.8.4. Market Size and Forecast, By End User
      • 8.3.9. Italy Neurotrophic Keratitis Market

        • 8.3.9.1. Market Size and Forecast, By Treatment Type
        • 8.3.9.2. Market Size and Forecast, By Surgical Intervention
        • 8.3.9.3. Market Size and Forecast, By Application
        • 8.3.9.4. Market Size and Forecast, By End User
      • 8.3.10. Spain Neurotrophic Keratitis Market

        • 8.3.10.1. Market Size and Forecast, By Treatment Type
        • 8.3.10.2. Market Size and Forecast, By Surgical Intervention
        • 8.3.10.3. Market Size and Forecast, By Application
        • 8.3.10.4. Market Size and Forecast, By End User
      • 8.3.11. UK Neurotrophic Keratitis Market

        • 8.3.11.1. Market Size and Forecast, By Treatment Type
        • 8.3.11.2. Market Size and Forecast, By Surgical Intervention
        • 8.3.11.3. Market Size and Forecast, By Application
        • 8.3.11.4. Market Size and Forecast, By End User
      • 8.3.12. Russia Neurotrophic Keratitis Market

        • 8.3.12.1. Market Size and Forecast, By Treatment Type
        • 8.3.12.2. Market Size and Forecast, By Surgical Intervention
        • 8.3.12.3. Market Size and Forecast, By Application
        • 8.3.12.4. Market Size and Forecast, By End User
      • 8.3.13. Rest Of Europe Neurotrophic Keratitis Market

        • 8.3.13.1. Market Size and Forecast, By Treatment Type
        • 8.3.13.2. Market Size and Forecast, By Surgical Intervention
        • 8.3.13.3. Market Size and Forecast, By Application
        • 8.3.13.4. Market Size and Forecast, By End User
    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Treatment Type

      • 8.4.3. Market Size and Forecast, By Surgical Intervention

      • 8.4.4. Market Size and Forecast, By Application

      • 8.4.5. Market Size and Forecast, By End User

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Neurotrophic Keratitis Market

        • 8.4.7.1. Market Size and Forecast, By Treatment Type
        • 8.4.7.2. Market Size and Forecast, By Surgical Intervention
        • 8.4.7.3. Market Size and Forecast, By Application
        • 8.4.7.4. Market Size and Forecast, By End User
      • 8.4.8. Japan Neurotrophic Keratitis Market

        • 8.4.8.1. Market Size and Forecast, By Treatment Type
        • 8.4.8.2. Market Size and Forecast, By Surgical Intervention
        • 8.4.8.3. Market Size and Forecast, By Application
        • 8.4.8.4. Market Size and Forecast, By End User
      • 8.4.9. India Neurotrophic Keratitis Market

        • 8.4.9.1. Market Size and Forecast, By Treatment Type
        • 8.4.9.2. Market Size and Forecast, By Surgical Intervention
        • 8.4.9.3. Market Size and Forecast, By Application
        • 8.4.9.4. Market Size and Forecast, By End User
      • 8.4.10. South Korea Neurotrophic Keratitis Market

        • 8.4.10.1. Market Size and Forecast, By Treatment Type
        • 8.4.10.2. Market Size and Forecast, By Surgical Intervention
        • 8.4.10.3. Market Size and Forecast, By Application
        • 8.4.10.4. Market Size and Forecast, By End User
      • 8.4.11. Australia Neurotrophic Keratitis Market

        • 8.4.11.1. Market Size and Forecast, By Treatment Type
        • 8.4.11.2. Market Size and Forecast, By Surgical Intervention
        • 8.4.11.3. Market Size and Forecast, By Application
        • 8.4.11.4. Market Size and Forecast, By End User
      • 8.4.12. Thailand Neurotrophic Keratitis Market

        • 8.4.12.1. Market Size and Forecast, By Treatment Type
        • 8.4.12.2. Market Size and Forecast, By Surgical Intervention
        • 8.4.12.3. Market Size and Forecast, By Application
        • 8.4.12.4. Market Size and Forecast, By End User
      • 8.4.13. Malaysia Neurotrophic Keratitis Market

        • 8.4.13.1. Market Size and Forecast, By Treatment Type
        • 8.4.13.2. Market Size and Forecast, By Surgical Intervention
        • 8.4.13.3. Market Size and Forecast, By Application
        • 8.4.13.4. Market Size and Forecast, By End User
      • 8.4.14. Indonesia Neurotrophic Keratitis Market

        • 8.4.14.1. Market Size and Forecast, By Treatment Type
        • 8.4.14.2. Market Size and Forecast, By Surgical Intervention
        • 8.4.14.3. Market Size and Forecast, By Application
        • 8.4.14.4. Market Size and Forecast, By End User
      • 8.4.15. Rest of Asia Pacific Neurotrophic Keratitis Market

        • 8.4.15.1. Market Size and Forecast, By Treatment Type
        • 8.4.15.2. Market Size and Forecast, By Surgical Intervention
        • 8.4.15.3. Market Size and Forecast, By Application
        • 8.4.15.4. Market Size and Forecast, By End User
    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Treatment Type

      • 8.5.3. Market Size and Forecast, By Surgical Intervention

      • 8.5.4. Market Size and Forecast, By Application

      • 8.5.5. Market Size and Forecast, By End User

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Neurotrophic Keratitis Market

        • 8.5.7.1. Market Size and Forecast, By Treatment Type
        • 8.5.7.2. Market Size and Forecast, By Surgical Intervention
        • 8.5.7.3. Market Size and Forecast, By Application
        • 8.5.7.4. Market Size and Forecast, By End User
      • 8.5.8. South Africa Neurotrophic Keratitis Market

        • 8.5.8.1. Market Size and Forecast, By Treatment Type
        • 8.5.8.2. Market Size and Forecast, By Surgical Intervention
        • 8.5.8.3. Market Size and Forecast, By Application
        • 8.5.8.4. Market Size and Forecast, By End User
      • 8.5.9. Saudi Arabia Neurotrophic Keratitis Market

        • 8.5.9.1. Market Size and Forecast, By Treatment Type
        • 8.5.9.2. Market Size and Forecast, By Surgical Intervention
        • 8.5.9.3. Market Size and Forecast, By Application
        • 8.5.9.4. Market Size and Forecast, By End User
      • 8.5.10. UAE Neurotrophic Keratitis Market

        • 8.5.10.1. Market Size and Forecast, By Treatment Type
        • 8.5.10.2. Market Size and Forecast, By Surgical Intervention
        • 8.5.10.3. Market Size and Forecast, By Application
        • 8.5.10.4. Market Size and Forecast, By End User
      • 8.5.11. Argentina Neurotrophic Keratitis Market

        • 8.5.11.1. Market Size and Forecast, By Treatment Type
        • 8.5.11.2. Market Size and Forecast, By Surgical Intervention
        • 8.5.11.3. Market Size and Forecast, By Application
        • 8.5.11.4. Market Size and Forecast, By End User
      • 8.5.12. Rest of LAMEA Neurotrophic Keratitis Market

        • 8.5.12.1. Market Size and Forecast, By Treatment Type
        • 8.5.12.2. Market Size and Forecast, By Surgical Intervention
        • 8.5.12.3. Market Size and Forecast, By Application
        • 8.5.12.4. Market Size and Forecast, By End User
  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Dompe Farmaceutici S.p.A.,

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Allergan, ReGenTree, LLC,

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. Alcon,

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Bausch And Lomb Incorporated,

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. CONTACARE,

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. OHTO Pharmaceutical Co., Ltd.,

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Pfizer, Inc.,

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Neuroptika,

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Santen Pharmaceutical Co., Ltd.,

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Johnson And Johnson,

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

    • 10.11. Grand Pharma, Co., Ltd.,

      • 10.11.1. Company Overview

      • 10.11.2. Key Executives

      • 10.11.3. Company Snapshot

      • 10.11.4. Operating Business Segments

      • 10.11.5. Product Portfolio

      • 10.11.6. Business Performance

      • 10.11.7. Key Strategic Moves and Developments

    • 10.12. Zhejiang CONBA Pharmaceutical Co., Ltd.

      • 10.12.1. Company Overview

      • 10.12.2. Key Executives

      • 10.12.3. Company Snapshot

      • 10.12.4. Operating Business Segments

      • 10.12.5. Product Portfolio

      • 10.12.6. Business Performance

      • 10.12.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL NEUROTROPHIC KERATITIS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL NEUROTROPHIC KERATITIS MARKET FOR ARTIFICIAL TEAR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL NEUROTROPHIC KERATITIS MARKET FOR RECOMBINANT HUMAN NERVE GROWTH FACTOR EYE DROP, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL NEUROTROPHIC KERATITIS MARKET FOR ANTIBIOTIC, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL NEUROTROPHIC KERATITIS MARKET FOR BANDAGE CONTACT LENSES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL NEUROTROPHIC KERATITIS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL NEUROTROPHIC KERATITIS MARKET, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL NEUROTROPHIC KERATITIS MARKET FOR TARSORRHAPHY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL NEUROTROPHIC KERATITIS MARKET FOR AMINOITIC MEMBRANE TRANSPLANTATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL NEUROTROPHIC KERATITIS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL NEUROTROPHIC KERATITIS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL NEUROTROPHIC KERATITIS MARKET FOR STAGE II, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL NEUROTROPHIC KERATITIS MARKET FOR STAGE II, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL NEUROTROPHIC KERATITIS MARKET FOR STAGE III, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL NEUROTROPHIC KERATITIS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL NEUROTROPHIC KERATITIS MARKET FOR BIOTECHNOLOGY COMPANY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL NEUROTROPHIC KERATITIS MARKET FOR HOSPITAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL NEUROTROPHIC KERATITIS MARKET FOR CLINIC, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL NEUROTROPHIC KERATITIS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA NEUROTROPHIC KERATITIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 25. U.S. NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 26. U.S. NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 27. U.S. NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 28. U.S. NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. CANADA NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 30. CANADA NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 31. CANADA NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 32. CANADA NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. MEXICO NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 34. MEXICO NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 35. MEXICO NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE NEUROTROPHIC KERATITIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. FRANCE NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 43. FRANCE NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. FRANCE NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. GERMANY NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 47. GERMANY NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 48. GERMANY NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 49. GERMANY NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 50. ITALY NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 51. ITALY NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 52. ITALY NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 53. ITALY NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 54. SPAIN NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 55. SPAIN NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 56. SPAIN NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 57. SPAIN NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 58. UK NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 59. UK NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 60. UK NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. UK NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. RUSSIA NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 63. RUSSIA NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 64. RUSSIA NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 65. RUSSIA NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 66. REST OF EUROPE NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 67. REST OF EUROPE NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 68. REST OF EUROPE NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 69. REST OF EUROPE NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. ASIA-PACIFIC NEUROTROPHIC KERATITIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 71. ASIA-PACIFIC NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 72. ASIA-PACIFIC NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 73. ASIA-PACIFIC NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 74. ASIA-PACIFIC NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 75. CHINA NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 76. CHINA NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 77. CHINA NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 78. CHINA NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 79. JAPAN NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 80. JAPAN NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 81. JAPAN NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 82. JAPAN NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 83. INDIA NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 84. INDIA NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 85. INDIA NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 86. INDIA NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH KOREA NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 88. SOUTH KOREA NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH KOREA NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH KOREA NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 91. AUSTRALIA NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 92. AUSTRALIA NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 93. AUSTRALIA NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 94. AUSTRALIA NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 95. THAILAND NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 96. THAILAND NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 97. THAILAND NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 98. THAILAND NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 99. MALAYSIA NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 100. MALAYSIA NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 101. MALAYSIA NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 102. MALAYSIA NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 103. INDONESIA NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 104. INDONESIA NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 105. INDONESIA NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 106. INDONESIA NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 107. REST OF ASIA PACIFIC NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 108. REST OF ASIA PACIFIC NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 109. REST OF ASIA PACIFIC NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 110. REST OF ASIA PACIFIC NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 111. LAMEA NEUROTROPHIC KERATITIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 112. LAMEA NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 113. LAMEA NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 114. LAMEA NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 115. LAMEA NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 116. BRAZIL NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 117. BRAZIL NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 118. BRAZIL NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 119. BRAZIL NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 120. SOUTH AFRICA NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 121. SOUTH AFRICA NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 122. SOUTH AFRICA NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 123. SOUTH AFRICA NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 124. SAUDI ARABIA NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 125. SAUDI ARABIA NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 126. SAUDI ARABIA NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 127. SAUDI ARABIA NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 128. UAE NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 129. UAE NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 130. UAE NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 131. UAE NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 132. ARGENTINA NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 133. ARGENTINA NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 134. ARGENTINA NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 135. ARGENTINA NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 136. REST OF LAMEA NEUROTROPHIC KERATITIS, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 137. REST OF LAMEA NEUROTROPHIC KERATITIS, BY SURGICAL INTERVENTION, 2022-2032 ($MILLION)
  • TABLE 138. REST OF LAMEA NEUROTROPHIC KERATITIS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 139. REST OF LAMEA NEUROTROPHIC KERATITIS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 140. DOMPE FARMACEUTICI S.P.A.,: KEY EXECUTIVES
  • TABLE 141. DOMPE FARMACEUTICI S.P.A.,: COMPANY SNAPSHOT
  • TABLE 142. DOMPE FARMACEUTICI S.P.A.,: OPERATING SEGMENTS
  • TABLE 143. DOMPE FARMACEUTICI S.P.A.,: PRODUCT PORTFOLIO
  • TABLE 144. DOMPE FARMACEUTICI S.P.A.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. ALLERGAN, REGENTREE, LLC,: KEY EXECUTIVES
  • TABLE 146. ALLERGAN, REGENTREE, LLC,: COMPANY SNAPSHOT
  • TABLE 147. ALLERGAN, REGENTREE, LLC,: OPERATING SEGMENTS
  • TABLE 148. ALLERGAN, REGENTREE, LLC,: PRODUCT PORTFOLIO
  • TABLE 149. ALLERGAN, REGENTREE, LLC,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. ALCON,: KEY EXECUTIVES
  • TABLE 151. ALCON,: COMPANY SNAPSHOT
  • TABLE 152. ALCON,: OPERATING SEGMENTS
  • TABLE 153. ALCON,: PRODUCT PORTFOLIO
  • TABLE 154. ALCON,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 155. BAUSCH AND LOMB INCORPORATED,: KEY EXECUTIVES
  • TABLE 156. BAUSCH AND LOMB INCORPORATED,: COMPANY SNAPSHOT
  • TABLE 157. BAUSCH AND LOMB INCORPORATED,: OPERATING SEGMENTS
  • TABLE 158. BAUSCH AND LOMB INCORPORATED,: PRODUCT PORTFOLIO
  • TABLE 159. BAUSCH AND LOMB INCORPORATED,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 160. CONTACARE,: KEY EXECUTIVES
  • TABLE 161. CONTACARE,: COMPANY SNAPSHOT
  • TABLE 162. CONTACARE,: OPERATING SEGMENTS
  • TABLE 163. CONTACARE,: PRODUCT PORTFOLIO
  • TABLE 164. CONTACARE,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 165. OHTO PHARMACEUTICAL CO., LTD.,: KEY EXECUTIVES
  • TABLE 166. OHTO PHARMACEUTICAL CO., LTD.,: COMPANY SNAPSHOT
  • TABLE 167. OHTO PHARMACEUTICAL CO., LTD.,: OPERATING SEGMENTS
  • TABLE 168. OHTO PHARMACEUTICAL CO., LTD.,: PRODUCT PORTFOLIO
  • TABLE 169. OHTO PHARMACEUTICAL CO., LTD.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 170. PFIZER, INC.,: KEY EXECUTIVES
  • TABLE 171. PFIZER, INC.,: COMPANY SNAPSHOT
  • TABLE 172. PFIZER, INC.,: OPERATING SEGMENTS
  • TABLE 173. PFIZER, INC.,: PRODUCT PORTFOLIO
  • TABLE 174. PFIZER, INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 175. NEUROPTIKA,: KEY EXECUTIVES
  • TABLE 176. NEUROPTIKA,: COMPANY SNAPSHOT
  • TABLE 177. NEUROPTIKA,: OPERATING SEGMENTS
  • TABLE 178. NEUROPTIKA,: PRODUCT PORTFOLIO
  • TABLE 179. NEUROPTIKA,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 180. SANTEN PHARMACEUTICAL CO., LTD.,: KEY EXECUTIVES
  • TABLE 181. SANTEN PHARMACEUTICAL CO., LTD.,: COMPANY SNAPSHOT
  • TABLE 182. SANTEN PHARMACEUTICAL CO., LTD.,: OPERATING SEGMENTS
  • TABLE 183. SANTEN PHARMACEUTICAL CO., LTD.,: PRODUCT PORTFOLIO
  • TABLE 184. SANTEN PHARMACEUTICAL CO., LTD.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 185. JOHNSON AND JOHNSON,: KEY EXECUTIVES
  • TABLE 186. JOHNSON AND JOHNSON,: COMPANY SNAPSHOT
  • TABLE 187. JOHNSON AND JOHNSON,: OPERATING SEGMENTS
  • TABLE 188. JOHNSON AND JOHNSON,: PRODUCT PORTFOLIO
  • TABLE 189. JOHNSON AND JOHNSON,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 190. GRAND PHARMA, CO., LTD.,: KEY EXECUTIVES
  • TABLE 191. GRAND PHARMA, CO., LTD.,: COMPANY SNAPSHOT
  • TABLE 192. GRAND PHARMA, CO., LTD.,: OPERATING SEGMENTS
  • TABLE 193. GRAND PHARMA, CO., LTD.,: PRODUCT PORTFOLIO
  • TABLE 194. GRAND PHARMA, CO., LTD.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 195. ZHEJIANG CONBA PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
  • TABLE 196. ZHEJIANG CONBA PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
  • TABLE 197. ZHEJIANG CONBA PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
  • TABLE 198. ZHEJIANG CONBA PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 199. ZHEJIANG CONBA PHARMACEUTICAL CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROTROPHIC KERATITIS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL NEUROTROPHIC KERATITIS MARKET
  • FIGURE 3. SEGMENTATION NEUROTROPHIC KERATITIS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN NEUROTROPHIC KERATITIS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALNEUROTROPHIC KERATITIS MARKET
  • FIGURE 11. NEUROTROPHIC KERATITIS MARKET SEGMENTATION, BY BY TREATMENT TYPE
  • FIGURE 12. NEUROTROPHIC KERATITIS MARKET FOR ARTIFICIAL TEAR, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. NEUROTROPHIC KERATITIS MARKET FOR RECOMBINANT HUMAN NERVE GROWTH FACTOR EYE DROP, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. NEUROTROPHIC KERATITIS MARKET FOR ANTIBIOTIC, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. NEUROTROPHIC KERATITIS MARKET FOR BANDAGE CONTACT LENSES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. NEUROTROPHIC KERATITIS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. NEUROTROPHIC KERATITIS MARKET SEGMENTATION, BY BY SURGICAL INTERVENTION
  • FIGURE 18. NEUROTROPHIC KERATITIS MARKET FOR TARSORRHAPHY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. NEUROTROPHIC KERATITIS MARKET FOR AMINOITIC MEMBRANE TRANSPLANTATION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. NEUROTROPHIC KERATITIS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. NEUROTROPHIC KERATITIS MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 22. NEUROTROPHIC KERATITIS MARKET FOR STAGE II, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. NEUROTROPHIC KERATITIS MARKET FOR STAGE II, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. NEUROTROPHIC KERATITIS MARKET FOR STAGE III, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. NEUROTROPHIC KERATITIS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 26. NEUROTROPHIC KERATITIS MARKET FOR BIOTECHNOLOGY COMPANY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. NEUROTROPHIC KERATITIS MARKET FOR HOSPITAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. NEUROTROPHIC KERATITIS MARKET FOR CLINIC, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 30. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 31. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 32. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 33. COMPETITIVE DASHBOARD
  • FIGURE 34. COMPETITIVE HEATMAP: NEUROTROPHIC KERATITIS MARKET
  • FIGURE 35. Top player positioning, 2022
  • FIGURE 36. DOMPE FARMACEUTICI S.P.A.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. DOMPE FARMACEUTICI S.P.A.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. DOMPE FARMACEUTICI S.P.A.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. ALLERGAN, REGENTREE, LLC,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. ALLERGAN, REGENTREE, LLC,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. ALLERGAN, REGENTREE, LLC,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. ALCON,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. ALCON,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. ALCON,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. BAUSCH AND LOMB INCORPORATED,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. BAUSCH AND LOMB INCORPORATED,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. BAUSCH AND LOMB INCORPORATED,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. CONTACARE,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. CONTACARE,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. CONTACARE,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. OHTO PHARMACEUTICAL CO., LTD.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. OHTO PHARMACEUTICAL CO., LTD.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. OHTO PHARMACEUTICAL CO., LTD.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. PFIZER, INC.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. PFIZER, INC.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. PFIZER, INC.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. NEUROPTIKA,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. NEUROPTIKA,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. NEUROPTIKA,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 60. SANTEN PHARMACEUTICAL CO., LTD.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. SANTEN PHARMACEUTICAL CO., LTD.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 62. SANTEN PHARMACEUTICAL CO., LTD.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 63. JOHNSON AND JOHNSON,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. JOHNSON AND JOHNSON,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 65. JOHNSON AND JOHNSON,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 66. GRAND PHARMA, CO., LTD.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 67. GRAND PHARMA, CO., LTD.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 68. GRAND PHARMA, CO., LTD.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 69. ZHEJIANG CONBA PHARMACEUTICAL CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 70. ZHEJIANG CONBA PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 71. ZHEJIANG CONBA PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Neurotrophic Keratitis Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers